Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose oral combination containing **lisinopril** and **arginine**. Lisinopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor that reduces blood pressure by inhibiting the conversion of angiotensin I to the vasoconstrictor angiotensin II, leading to reduced aldosterone secretion and decreased vasopressor activity. Arginine is a semi-essential amino acid with vasodilatory properties, often used to support vascular function. The combination is supplied as a kit (as in Lytensopril or Lytensopril-90) for oral administration and is indicated for management of **hypertension** and as adjunctive therapy for **heart failure** or **acute myocardial infarction**. The inclusion of arginine may support endothelial function but is not the main antihypertensive component; clinical efficacy is primarily due to lisinopril[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine + lisinopril.